Open Access<p>Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant</p>
Author(s) -
Chiao-Fang Teng,
TsaiChung Li,
Ting Wang,
Tzu-Hua Wu,
John Wang,
HungWei Wu,
WoeiCherng Shyu,
IhJen Su,
Long-Bin Jeng
Publication year - 2020
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s282818
Subject(s) - hepatocellular carcinoma , hepatitis b virus , immunohistochemistry , mutant , cancer research , cancer , pd l1 , immune system , medicine , liver cancer , hepatitis b , carcinoma , biology , virus , pathology , virology , gene , immunology , immunotherapy , biochemistry
Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC), a leading cause of cancer-related death worldwide. The HCC patients who harbor HBV pre-S2 mutant, an oncoprotein that plays key roles in HCC development, have been closely associated with a worse prognosis after curative surgical resection, suggesting an urgent need for alternative therapeutic options to improve their survival. In this study, we aimed to evaluate the expression profiles of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1), two of the most well-studied immune checkpoint molecules that promote tumor immune evasion, in tumor of the pre-S2 mutant-positive/high HCC patients.